Company profile · Biotech & medical
SynCore Biotechnology
杏國新藥股份有限公司 · 4192
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
SynCore Biotechnology is currently mainly in the stage of new drug R&D, and its sales consist of drugs, functional foods, and technical service income from commissioned testing and research services.[1]
The company develops products and services including anti-cancer drugs, functional foods, and technical services.[1]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$2m | -0.4% | -0.4% |
2024-11 to 2026-10, monthly revenue.
Facts
| Full English name | SynCore Biotechnology Co.,Ltd |
|---|---|
| Chinese name | 杏國新藥股份有限公司 |
| Stock code | 4192 (TPEx) |
| Industry | Biotech & medical |
| Founded | 26 Jun 2008 |
| Listed | 28 Oct 2014 |
| Paid-in capital | NT$352m |
| Chairman | 陳至孝 |
| President | 王惠弘 |
| Headquarters | 84 CHUNG SHAN RD.,CHUNG SHAN VILLAGE TUNG-SHAN SHINE , I-LAN 269 , TAIWAN. |
| Website | http://www.syncorebio.com |
| Official business description | A.食品顧問業 B.藥品檢驗業 C.生物技術服務業 D.西藥批發業 · E.智慧財產權業 F.除許可業務外，經營法令非禁止或限制之業務 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- Annual report 2025 (English), business scope · annual_report · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list